CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade XBiotech Inc. - XBIT CFD

    9.33
    1.52%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.11
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    XBiotech Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 9.19
    Open* 8.98
    1-Year Change* 153.67%
    Day's Range* 8.98 - 9.38
    52 wk Range 3.05-6.69
    Average Volume (10 days) 26.10K
    Average Volume (3 months) 399.01K
    Market Cap 146.10M
    P/E Ratio -100.00K
    Shares Outstanding 30.44M
    Revenue 300.00K
    EPS -0.76
    Dividend (Yield %) N/A
    Beta 1.37
    Next Earnings Date Mar 13, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 15, 2024 9.33 0.35 3.90% 8.98 9.38 8.98
    Apr 12, 2024 9.19 0.31 3.49% 8.88 9.43 8.88
    Apr 11, 2024 9.48 -0.23 -2.37% 9.71 9.79 9.05
    Apr 10, 2024 9.82 0.59 6.39% 9.23 9.90 8.97
    Apr 9, 2024 9.25 -0.28 -2.94% 9.53 9.54 8.97
    Apr 8, 2024 9.66 1.45 17.66% 8.21 9.79 8.21
    Apr 5, 2024 8.17 -0.93 -10.22% 9.10 9.42 8.03
    Apr 4, 2024 9.26 0.80 9.46% 8.46 9.45 8.40
    Apr 3, 2024 8.37 -0.09 -1.06% 8.46 9.36 8.29
    Apr 2, 2024 8.40 0.52 6.60% 7.88 8.40 7.51
    Apr 1, 2024 7.81 -0.17 -2.13% 7.98 7.98 7.73
    Mar 28, 2024 8.03 -0.08 -0.99% 8.11 8.15 7.64
    Mar 27, 2024 7.89 0.18 2.33% 7.71 8.01 7.64
    Mar 26, 2024 7.95 0.83 11.66% 7.12 8.12 7.12
    Mar 25, 2024 7.43 0.20 2.77% 7.23 7.44 6.98
    Mar 22, 2024 7.41 0.22 3.06% 7.19 7.44 6.94
    Mar 21, 2024 7.19 0.05 0.70% 7.14 7.22 6.98
    Mar 20, 2024 7.08 0.07 1.00% 7.01 7.15 6.70
    Mar 19, 2024 7.09 0.66 10.26% 6.43 7.40 6.43
    Mar 18, 2024 6.60 0.86 14.98% 5.74 6.96 5.74

    XBiotech Inc. Events

    Time (UTC) Country Event
    Wednesday, May 8, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q1 2024 XBiotech Inc Earnings Release
    Q1 2024 XBiotech Inc Earnings Release

    Forecast

    -

    Previous

    -
    Friday, June 21, 2024

    Time (UTC)

    15:00

    Country

    US

    Event

    XBiotech Inc Annual Shareholders Meeting
    XBiotech Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Friday, August 9, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q2 2024 XBiotech Inc Earnings Release
    Q2 2024 XBiotech Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 4.01 18.394 43.997 0 0
    Total Operating Expense 38.5 43.476 62.273 -718.767 20.994
    Selling/General/Admin. Expenses, Total 6.305 9.388 18.198 7.143 5.269
    Research & Development 31.544 28.268 9.527 24.09 15.725
    Operating Income -34.49 -25.082 -18.276 718.767 -20.994
    Interest Income (Expense), Net Non-Operating 1.023 -0.244 5.952 -0.324 -0.148
    Other, Net -0.121 -0.132 -0.503 0.01 0.004
    Net Income Before Taxes -33.588 -25.458 -12.827 718.453 -21.138
    Net Income After Taxes -32.9 -17.414 -11.221 668.629 -21.138
    Net Income Before Extra. Items -32.9 -17.414 -11.221 668.629 -21.138
    Net Income -32.9 -17.414 -11.221 668.629 -21.138
    Income Available to Common Excl. Extra. Items -32.9 -17.414 -11.221 668.629 -21.138
    Income Available to Common Incl. Extra. Items -32.9 -17.414 -11.221 668.629 -21.138
    Diluted Net Income -32.9 -17.414 -11.221 668.629 -21.138
    Diluted Weighted Average Shares 30.4393 30.0434 30.8235 46.3195 35.8043
    Diluted EPS Excluding Extraordinary Items -1.08084 -0.57963 -0.36404 14.4352 -0.59038
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -1.08084 -0.57963 -0.36404 3.91043 -0.59038
    Unusual Expense (Income) 0 0 -750
    Revenue 4.01 18.394 43.997
    Cost of Revenue, Total 0.651 5.82 34.548
    Gross Profit 3.359 12.574 9.449
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0.3 1.68 1.53
    Revenue 0 0 0.3 1.68 1.53
    Cost of Revenue, Total 0 0 0.016 0.215 0.207
    Gross Profit 0 0 0.284 1.465 1.323
    Total Operating Expense 13.258 7.145 8.462 8.069 13.624
    Selling/General/Admin. Expenses, Total 1.992 0.915 1.129 0.84 3.023
    Research & Development 11.266 6.23 7.317 7.014 10.394
    Operating Income -13.258 -7.145 -8.162 -6.389 -12.094
    Interest Income (Expense), Net Non-Operating 3.837 3.162 5.539 -3.868 -2.039
    Other, Net 0.75 0.13 -0.002 0 -0.119
    Net Income Before Taxes -8.671 -3.853 -2.625 -10.257 -14.252
    Net Income After Taxes -8.742 -3.816 -3.203 -12.658 -11.644
    Net Income Before Extra. Items -8.742 -3.816 -3.203 -12.658 -11.644
    Net Income -8.742 -3.816 -3.203 -12.658 -11.644
    Income Available to Common Excl. Extra. Items -8.742 -3.816 -3.203 -12.658 -11.644
    Income Available to Common Incl. Extra. Items -8.742 -3.816 -3.203 -12.658 -11.644
    Diluted Net Income -8.742 -3.816 -3.203 -12.658 -11.644
    Diluted Weighted Average Shares 30.4391 30.4393 30.4393 30.4393 30.4393
    Diluted EPS Excluding Extraordinary Items -0.2872 -0.12536 -0.10523 -0.41584 -0.38253
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.2872 -0.12536 -0.10523 -0.41584 -0.38253
    Other Operating Expenses, Total
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 219.843 246.87 325.875 716.263 17.016
    Cash and Short Term Investments 217.478 236.983 237.366 714.594 15.823
    Cash & Equivalents 157.306 236.983 237.366 714.594 15.823
    Prepaid Expenses 0.601 0.934 0.582 1.669 1.193
    Total Assets 246.103 275.177 353.744 816.877 44.345
    Property/Plant/Equipment, Total - Net 26.26 28.307 27.336 25.171 27.329
    Property/Plant/Equipment, Total - Gross 42.755 44.039 40.447 36.9 36.695
    Accumulated Depreciation, Total -16.495 -15.731 -13.111 -11.729 -9.366
    Total Current Liabilities 4.066 3.453 3.984 60.19 2.944
    Accounts Payable 2.408 2.069 2.491 2.149 1.653
    Accrued Expenses 1.603 1.374 1.351 4.18 1.291
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 5.701 5.792 5.105 61.246 2.947
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 1.576 1.466 1.121 1.056 0.003
    Total Equity 240.402 269.385 348.639 755.631 41.398
    Common Stock 267.325 262.263 249.805 324.808 279.353
    Retained Earnings (Accumulated Deficit) -27.749 5.151 97.568 430.929 -237.7
    Other Equity, Total 0.826 1.971 1.266 -0.106 -0.255
    Total Liabilities & Shareholders’ Equity 246.103 275.177 353.744 816.877 44.345
    Total Common Shares Outstanding 30.4393 30.4393 29.3044 41.5196 35.8998
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Note Receivable - Long Term 0 75
    Other Long Term Assets, Total 0 0.533 0.443
    Other Current Liabilities, Total 0.055 0.01 0.142 53.861
    Total Receivables, Net 1.764 8.953 85.75
    Accounts Receivable - Trade, Net 1.216 0 4.113
    Other Current Assets, Total 0 2.177
    Deferred Income Tax 0.059 0.873
    Short Term Investments 60.172
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 204.402 209.512 216.284 219.843 223.427
    Cash and Short Term Investments 202.191 204.771 212.662 217.478 220.1
    Cash & Equivalents 202.191 143.391 152.484 157.306 160.568
    Total Receivables, Net 1.332 3.794 2.919 1.764 2.706
    Accounts Receivable - Trade, Net 0.881 3.217 2.371 1.216 1.53
    Prepaid Expenses 0.879 0.947 0.703 0.601 0.621
    Other Current Assets, Total
    Total Assets 229.599 235.136 242.121 246.103 250.834
    Property/Plant/Equipment, Total - Net 25.197 25.624 25.837 26.26 26.635
    Other Long Term Assets, Total 0.772
    Total Current Liabilities 5.294 4.45 3.618 4.066 3.578
    Accounts Payable 1.468 1.816 1.357 2.408 1.376
    Accrued Expenses 3.667 2.634 2.206 1.603 1.988
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.159 0 0.055 0.055 0.214
    Total Liabilities 6.94 6.073 5.216 5.701 6.025
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 1.646 1.623 1.598 1.576 1.575
    Total Equity 222.659 229.063 236.905 240.402 244.809
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 269.89 268.93 268.03 267.325 266.287
    Retained Earnings (Accumulated Deficit) -47.671 -40.307 -31.565 -27.749 -24.546
    Other Equity, Total 0.44 0.44 0.44 0.826 3.068
    Total Liabilities & Shareholders’ Equity 229.599 235.136 242.121 246.103 250.834
    Total Common Shares Outstanding 30.437 30.4357 30.4393 30.4393 30.4393
    Deferred Income Tax 0 0 0 0.059 0.872
    Short Term Investments 0 61.38 60.178 60.172 59.532
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -32.9 -17.414 -11.221 668.629 -21.138
    Cash From Operating Activities -14.824 69.445 -65.149 -18.27 -16.537
    Cash From Operating Activities 2.614 2.648 2.238 2.361 2.433
    Non-Cash Items 6.646 6.64 10.404 -747.086 1.66
    Changes in Working Capital 8.816 77.038 -66.48 57.826 0.508
    Cash From Investing Activities -63.892 -3.525 -3.727 674.796 -0.122
    Capital Expenditures -0.585 -3.525 -3.727 -0.204 -0.122
    Cash From Financing Activities 0 -67.008 -409.724 42.096 0.201
    Financing Cash Flow Items 0 0 0.302
    Issuance (Retirement) of Stock, Net 0 7.995 -409.724 41.794 0.201
    Foreign Exchange Effects -0.961 0.705 1.372 0.149 0.513
    Net Change in Cash -79.677 -0.383 -477.228 698.771 -15.945
    Other Investing Cash Flow Items, Total -63.307 0 0 675
    Deferred Taxes 0 0.533 -0.09
    Cash Taxes Paid 0 54.087
    Total Cash Dividends Paid 0 -75.003
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -3.816 -32.9 -29.697 -17.039 -5.395
    Cash From Operating Activities -4.808 -14.824 -17.527 -11.5 -5.123
    Cash From Operating Activities 0.443 2.614 2.171 1.437 0.71
    Non-Cash Items -0.833 6.646 4.024 2.896 1.448
    Changes in Working Capital -0.543 8.816 6.748 1.629 -1.886
    Cash From Investing Activities -0.006 -63.892 -59.985 -0.243 -0.161
    Capital Expenditures -0.006 -0.585 -0.453 -0.243 -0.161
    Cash From Financing Activities 0 0 0 0
    Issuance (Retirement) of Stock, Net 0 0 0 0
    Foreign Exchange Effects -0.008 -0.961 1.097 0.553 0.122
    Net Change in Cash -4.822 -79.677 -76.415 -11.19 -5.162
    Deferred Taxes -0.059 0 -0.773 -0.423 0
    Financing Cash Flow Items
    Total Cash Dividends Paid 0 0
    Other Investing Cash Flow Items, Total -63.307 -59.532

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    XBiotech Inc. Company profile

    About XBiotech Inc

    XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases. The Company is engaged in the development of biotech manufacturing technologies designed to flexibly produce therapies. It has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. It has also developed commercial scale manufacturing technology that reduces the time to launch new product candidates. It is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. The Company's True Human antibody therapeutics are developed in-house using its discovery platform.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, XBiotech Inc revenues decreased 58% to $18.4M. Net loss increased 55% to $17.4M. Revenues reflect Clinical trial service revenue decrease of 98% to $394K, Other revenue decrease from $22K to $0K. Higher net loss reflects Research and Development increase from $3.3M to $14M (expense), Salaries and related expenses increase from $2.6M to $12.2M (expense).

    Industry: Bio Therapeutic Drugs

    5217 Winnebago Lane
    AUSTIN
    TEXAS 78744
    US

    Income Statement

    • Annual
    • Quarterly

    News

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    Higher CPI leaves traders unfazed as US equities continue to build momentum

    The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

    12:42, 15 March 2024

    People also watch

    ETH/USD

    3,100.30 Price
    +0.280% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    63,447.40 Price
    +0.260% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    Gold

    2,371.56 Price
    -0.600% 1D Chg, %
    Long position overnight fee -0.0188%
    Short position overnight fee 0.0106%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    US100

    17,706.40 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading